Pfizer Inc. has announced that the US Food and Drug Administration (FDA) has approved Lyrica CR (pregabalin) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and the management of postherpetic neuralgia (PHN).
Dosage/administration: Lyrica CR should be administered once daily after an evening meal. It should be swallowed whole and should not be split, crushed, or chewed. The initial dose for DPN is 165 mg/day; the maximum dose is 330 mg/day within 1 week. For PHN, the initial dose is 165 mg/day; the maximum dose is 330 mg/day within 1 week, with a maximum dose of 660 mg/day.
Adverse reactions: The most common adverse reactions reported with Lyrica CR were dizziness, somnolence, headache, fatigue, peripheral edema, nausea, blurred vision, dry mouth, and weight gain.
US FDA approves LYRICA CR (pregabalin) extended-release tablets CV. [news release]. New York, NY: Pfizer Inc. October 12, 2017. http://press.pfizer.com/press-release/us-fda-approves-lyrica-cr-pregabalin-extended-release-tablets-cv. Accessed October 30, 2017.
This Week's Must Reads
Fully Automated Test Gauges Processing Speed in MS, MS Mult Scler; ePub 2018 Aug 6; Patel, Shen, et al
Inflammation and Disability in Progressive-Onset MS, JAMA Neurology; ePub 2018 Aug 6; Hughes, et al
Mental Health’s Impact on Falls in Patients with MS, Mult Scler Relat Disord; ePub 2018 Jul 26; Kalron, et al
House-Call-Based Practice Viable for Advanced MS, Int J MS Care; ePub 2018 Aug 7; Healey, Zabad, et al
Detection of Chronic Active MS Lesions on 3T MRI, AJNR Am J Neuroradiol; 2018 Jul; Absinta, et al
Must Reads in FDA Actions
FDA Approves Xeomin for Excessive Drooling, Merz North America news release; 2018 Jul 3
FDA Approves Epidiolex for Rare Epilepsy Forms, FDA news release: 2018 Jun 25
FDA Approves Medtronic’s DBS Therapy for Epilepsy, Medtronic news release; 2018 May 1
FDA Approves Expanded Use of Exparel Nerve Block, Pacira news release; 2018 Apr 6
FDA Approves Hizentra for CIDP Treatment, CSL Behring news release; 2018 Mar 16